• 1
    Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am. J. Gastroenterol. 2003; 98: 9607.
    Direct Link:
  • 2
    Younossi ZM, Diehl AM, Ong JP. Nonalcoholic fatty liver disease: an agenda for clinical research. Hepatology 2002; 35: 74652.
  • 3
    Adams LA, Lymp JF, St Sauver J et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005; 129: 11321.
  • 4
    Sorensen HT, Mellemkjaer L, Jepsen P et al. Risk of cancer in patients hospitalized with fatty liver: a Danish cohort study. J. Clin. Gastroenterol. 2003; 36: 3569.
  • 5
    Browning JD, Szczepaniak LS, Dobbins R et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004; 40: 138795.
  • 6
    Chitturi S, Abeygunasekera S, Farrell GC et al. NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002; 35: 3739.
  • 7
    Marchesini G, Bugianesi E. NASH as part of the metabolic (insulin resistance) syndrome. In: FarrellGC, HallP, GeorgeJ, McCulloughAJ, eds. Fatty Liver Disease: NASH And Related Disorders. Malden, MA: Blackwell Publishing, 2005; 5565.
  • 8
    Hamaguchi M, Kojima T, Takeda N et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann. Intern. Med. 2005; 143: 7228.
  • 9
    Kim HJ, Kim HJ, Lee KE et al. Metabolic significance of nonalcoholic fatty liver disease in nonobese, nondiabetic adults. Arch. Intern. Med. 2004; 164: 216975.
  • 10
    Ryan MC, Wilson AM, Slavin J, Best JD, Jenkins AJ, Desmond PV. Associations between liver histology and severity of the metabolic syndrome in subjects with nonalcoholic fatty liver disease. Diabetes Care 2005; 28: 12224.
  • 11
    Tuomilehto J, Lindstrom J, Eriksson JG et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N. Engl. J. Med. 2001; 344: 134350.
  • 12
    Knowler WC, Barrett-Connor E, Fowler SE et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med. 2002; 346: 393403.
  • 13
    Ramachandran A, Snehalatha C, Mary S et al. The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia 2006; 49: 28997.
  • 14
    Pan XR, Li GW, Hu YH et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 1997; 20: 53744.
  • 15
    George J, Farrell GC. Practical approach to the diagnosis and management of people with fatty liver diseases. In: FarrellGC, HallP, GeorgeJ, McCulloughAJ, eds. Fatty Liver Disease: NASH and Related Disorders. Malden, MA: Blackwell Publishing, 2005; 18193.
  • 16
    Huang MA, Greenson JK, Chao C et al. One-year intense nutritional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: a pilot study. Am. J. Gastroenterol. 2005; 100: 107281.
    Direct Link:
  • 17
    Okita M, Hayashi M, Sasagawa T et al. Effect of a moderately energy-restricted diet on obese patients with fatty liver. Nutrition 2001; 17: 5427.
  • 18
    Ueno T, Sugawara H, Sujaku K et al. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J. Hepatol. 1997; 27: 1037.
  • 19
    Hickman IJ, Jonsson JR, Prins JB et al. Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life. Gut 2004; 53: 4139.
  • 20
    Hickman IJ, Clouston AD, Macdonald GA et al. Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C. Gut 2002; 51: 8994.
  • 21
    Suzuki A, Lindor K, Saver JS et al. Effect of changes on body weight and lifestyle in nonalcoholic fatty liver disease. J. Hepatol. 2005; 43: 106066.
  • 22
    Kugelmas M, Hill DB, Vivian B, Marsano L, Mcclain CJ. Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E. Hepatology 2003; 38: 41319.
  • 23
    Osland EJ, Powell EE, Banks M, Jonsson JR, Hickman IJ. Obesity management in liver clinics: translation of research into clinical practice. J. Gastroenterol. Hepatol. 2007; 22: 5049.
  • 24
    Hickman I, Powell E, Jonsson J, Ash S. Intensive dietary intervention improves weight maintenance in the management of non-alcoholic fatty liver disease. J. Hepatol. 2002; 36: 256.
  • 25
    Mendes FD, Lindor KD. Recent advances in the treatment of non-alcoholic fatty liver disease. Expert Opin. Investig. Drugs 2005; 14: 2935.
  • 26
    Baranowski T, Cullen KW, Nicklas T, Thompson D, Baranowski J. Are current health behavioral change models helpful in guiding prevention of weight gain efforts? Obes. Res. 2003; 11: 23S43S.
  • 27
    Prochaska JO, Velicer WF. The transtheoretical model of health behavior change. Am. J. Health Promot. 1997; 12: 3848.
  • 28
    Sheldon KM, Williams GC, Joiner T. Self-Determination Theory in the Clinic: Motivating Physical and Mental Health. New Haven, CT: Yale University Press, 2003.
  • 29
    Rollnick S, Mason P, Butler C. Health Behavior Change; A Guide for Practitioners. New York: Churchill Livingstone, Harcourt Publishers Limited, 2000.
  • 30
    Saris WH, Blair SN, Van Baak MA et al. How much physical activity is enough to prevent unhealthy weight gain? Outcome of the IASO 1st Stock Conference and consensus statement. Obes. Rev. 2003; 4: 10114.
  • 31
    NHMRC. Clinical practice guidelines for the management of overweight and obesity in adults. Canberra: National Health and Medical Research Council, Commonwealth of Australia. 2003.
  • 32
    Marfell-Jones M, Olds T, Steckler A, Carter L. International Standards for Anthropometric Assessment. Potchefstroom, South Africa: ISAK, 2006.
  • 33
    Brown WJ, Trost SG, Bauman A, Mummery K, Owen N. Test-retest reliability of four physical activity measures used in population surveys. J. Sci. Med. Sport 2004; 7: 20515.
  • 34
    ACSM. American College of Sports Medicine's (ACSM) Guidelines for Exercise Testing and Prescription. New York: Lippincott, Williams and Wilkins, 2005.
  • 35
    Expert Panel on Detection E, Treatment of High Blood Cholesterol in A. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). 248697.
  • 36
    Farrell GC, George J, De la M, Hall P, McCullough AJ. Fatty Liver Disease: NASH and Related Disorders. London: Blackwell Publishing Ltd, 2005.
  • 37
    Bouneva I, Kirby DF. Management of nonalcoholic fatty liver disease: weight control. Clin. Liver Dis. 2004; 8: 693713.
  • 38
    Chavez-Tapia NC, Barrientos-Gutierrez T, Tellez-Avila FI, Sanchez-Avila F, Montano-Reyes MA, Uribe M. Insulin sensitizers in treatment of nonalcoholic fatty liver disease: systematic review. World J. Gastroenterol. 2006; 12: 782631.
  • 39
    Federico A, Trappoliere M, Loguercio C. Treatment of patients with non-alcoholic fatty liver disease: current views and perspectives. Dig. Liver Dis. 2006; 38: 789801.
  • 40
    Chitturi S, Farrell GC, Hashimoto E et al. Non-alcoholic fatty liver disease in the Asia-Pacific region: definitions and overview of proposed guidelines. J. Gastroenterol. Hepatol. 2007; 22: 77887.
  • 41
    Marchesini G, Marzocchi R, Agostini F, Bugianesi E. Nonalcoholic fatty liver disease and the metabolic syndrome. Curr. Opin. Lipidol. 2005; 16: 4217.
  • 42
    Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, Bellentani S. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology 2005; 42: 4452.
  • 43
    Belfort R, Harrison SA, Brown K et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N. Engl. J. Med. 2006; 355: 2297307.